Hyundai Bioscience Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jong-Won Choi

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Mar 14

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Feb 07

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Jan 03

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Nov 29

Geschäftsführer

Jong-Won Choi (57 yo)

no data

Amtszeit

Choi Jong-Won serves as a Co-Chief Executive Officer of Hyundai IT Corp. Choi Jong-Won served as Managing Director of KRPM, Korea Telecom Data, Inc., and Elli Partners. Choi Jong-Won served as Director of...

Hyundai Bioscience Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060).

Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion.

Full year 2023 earnings released: ₩365 loss per share (vs ₩402 loss in FY 2022)

New major risk - Share price stability

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

New major risk - Share price stability

Full year 2022 earnings released: ₩402 loss per share (vs ₩543 loss in FY 2021)

Less than half of directors are independent

Vector Inc. (TSE:6058) agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410) for KRW 13.7 billion.

Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA

Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials

Less than half of directors are independent

Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day high: ₩37,100

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

New 90-day high: ₩13,650

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day low: ₩10,150

New 90-day low: ₩10,800

Hyundai Bioscience Co., Ltd. announced that it has received KRW 32 billion in funding from a group of investors

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 32 billion in funding from a group of investors

Geschäftsführer

Amtszeit